BMEA רווח נקי למניה ב-12 החודשים האחרונים biomeafusion.com
Biomea Fusion, Inc. (BMEA) plans to generate revenue through the implementation of BMF-219 covalent inhibitors to combat oncology and diabetes. Annual net income per share reflects the dynamics of this process, where -0.31 captures the current state of the parameter. The issuer monetizes its intellectual property via enzyme modulation, delegating research to external laboratories without losing control over its patents.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_BMEA_-_Biomea-Fusion-Inc._-_Earnings-per-share-for-the-last-four-quarters "Biomea - רווח נקי למניה (EPS TTM) BMEA (תקופה 04.07.2022 - 14.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Biomea Fusion Corp (BMEA)
The stability of the healthcare sector and the insulation of metabolic disease research from geopolitical risks create a predictable backdrop for the valuation of Biomea Fusion, Inc. (BMEA). By analyzing the rolling annual earnings per share, an investor can see the final financial result distributed across the total share issuance, allowing for an objective comparison of current business yields against market offerings and a determination of the asset's premium.
